ANNOUNCEMENT 07 Dec 2016

On December 7th, 2016, the Innovation Network Corporation of Japan (INCJ) made an additional investment in the Japanese corporation ーNapaJen Pharma, Inc.

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

INCJ (2016) 日本発、全身性の核酸医薬の開発を目指す バイオベンチャーNapajen Pharma, Inc.への追加投資を決定 「From Japan, decided to invest additional investment in bio venture Napajen Pharma, Inc. aiming to develop systemic nucleic acid medicine」
Available at:
https://www.incj.co.jp/news/2016/20161207.html

Inception date: 07 Dec 2016 | Removal date: open ended

Capital injection and equity stakes (including bailouts)

On December 7th, 2016, the INCJ announced an additional 12 million USD investment in the equity of NapaJen Pharma, Inc. The injection shall support the company's research and manufacturing of nucleic acid medicines and drug delivery system. Napajet's headquarters is located in California. 

This is the second capital investment in Napajet, in 2014 INCJ made a 9 million USD capital investment.

About the Innovation Network Corporation of Japan (INCJ)
In 2009, INCJ was created as a public-private investment fund to financially support industries "next-generation businesses". INCJ supports projects that "combine technologies and varied expertise across industries and materialize open innovation.". According to the INCJ website, the fund has an investment capacity of up to USD 20 billion. Although characterized as a public-private partnership, in fact only 0.1 billion of the 2.6 billion USD invested in the fund was provided by the private sector. The rest came from the Japanese government. Of the 0.1 billion USD said to be contributed by the private sector, 13.6 million USD was in fact provided by the Development Bank of Japan, a state-owned bank.

AFFECTED SECTORS